Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
Rhea-AI Summary
Spero Therapeutics (Nasdaq: SPRO) said it will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, after market close. The company noted it does not intend to host a conference call for the release.
Investors should expect a written release and related materials on that date rather than a live audio briefing.
Positive
- None.
Negative
- None.
News Market Reaction – SPRO
In the Mar 19 session, SPRO gained 0.41%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Regulatory milestone | Positive | +1.3% | GSK resubmitted NDA for tebipenem HBr, triggering a $25M milestone. |
| Nov 28 | Equity compensation | Neutral | +3.0% | Inducement grant of 90,000 RSUs to a new employee under equity plan. |
| Nov 13 | Quarterly earnings | Positive | -1.2% | Q3 2025 results with positive PIVOT-PO data and reduced net loss. |
| Nov 04 | Earnings date set | Neutral | +3.4% | Announcement of Q3 2025 earnings date and decision not to host a call. |
| Oct 21 | Clinical trial data | Positive | +3.5% | Phase 3 PIVOT-PO met primary endpoint and was stopped early for efficacy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory milestones have generally seen modest positive alignment, while fundamental quarter results have produced at least one negative divergence.
Over the last six months, SPRO has advanced tebipenem HBr with positive Phase 3 PIVOT-PO data and an NDA resubmission by GSK, including a $25 million milestone tied to the filing. Quarterly updates showed a narrower Q3 2025 net loss and cash of $48.6 million, alongside discontinued non-core programs. Prior earnings-date announcements, like the Q3 2025 call timing, triggered modest gains. Today’s scheduling of Q4 and full-year 2025 results continues that cadence of regular operational updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
